Navigation Links
Schering-Plough Reports Financial Results for 2009 First Quarter
Date:4/21/2009

ares in approximately 50 percent of the profits of the joint venture with Merck, although there are different profit-sharing arrangements for the cholesterol products in countries around the world. Schering-Plough records its share of the income from operations in "Equity income," which totaled $400 million in the 2009 first quarter, as compared to $517 million in the first quarter of 2008.

Schering-Plough does not record sales of its cholesterol joint venture and incurs substantial costs such as selling, general and administrative costs that are not reflected in "Equity income" and are borne by the overall cost structure of Schering-Plough. As a result, Schering-Plough's gross margin and ratios of selling, general and administrative (SG&A) expenses and R&D expenses as a percentage of sales do not reflect the benefit of the impact of the cholesterol joint venture's operating results.

Schering-Plough's gross margin on a GAAP basis was unfavorably affected by purchase accounting adjustments and totaled 68.2 percent for the 2009 first quarter as compared to 54.1 percent in the 2008 period. Excluding purchase accounting adjustments, the gross margin percentage increased to 71.0 percent for the first quarter of 2009 as compared to 68.9 percent for the first quarter of 2008, primarily due to a favorable impact from foreign exchange.

SG&A expenses were $1.5 billion in the first quarter of 2009, an 11 percent decrease versus the first quarter of 2008 primarily due to the impact of foreign exchange and PTP actions.

Research and development spending for the 2009 first quarter totaled $804 million, a 9 percent decline due to PTP actions, the impact of foreign exchange and the timing of clinical trials and related activities.

Update on Merger with Merck

The previously announced merger with Merck remains on track. Merger pre-integration planning teams h
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine news :

1. EPA Names Schering-Plough 2009 EPA ENERGY STAR(R) Partner of the Year
2. Settlement Hearing on Schering-Plough Corporation Securities Litigation to be Held on June 1, 2009 at 2:00 P.M.
3. Schering-Plough Withdraws From Barclays Capital Global Healthcare Conference
4. Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
5. Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
6. Schering-Plough Selects Benefit Advocates for Health Advocacy
7. Schering-Plough Schedules Conference Call and Webcast for 2008 Fourth Quarter and Full Year Earnings
8. Schering-Plough Announces European Submission of Fertility Medicine Corifollitropin Alfa
9. Lupin Announces Litigation Settlement with Schering-Plough Corporation for Desloratadine(R)
10. Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C
11. Schering-Plough to Webcast R&D Update Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Reducing the amount of alcoholic beverages consumed, ... including a reduced risk of coronary heart disease, ... according to a new multi-center study published in ... Perelman School of Medicine at the University of ... studies which suggest that consuming light-to-moderate amounts of ...
(Date:7/10/2014)... students looking to bump up their grade point averages ... time in a library or study hall, but in ... that students who were members of the recreational sports ... and sophomore years had higher GPAs than those who ... with memberships stayed in school longer. An increase of ...
(Date:7/10/2014)... studies have shown that more severe illness and even ... secondary respiratory infection after developing influenza. Now, however, a ... determined that if you reverse the order of infection, ... may actually protect against a bad case of the ... protein pneumolysin, which is described as a bacterial virulence ...
(Date:7/10/2014)... cancer were more likely to be diagnosed with ... and survived for shorter times than prostate cancer ... has found. , The negative outcomes may be ... against the mentally ill, depression,s impact on biological ... in his general health and disinterest in receiving ...
(Date:7/10/2014)... who experience hot flashes are unlikely to talk much ... silent suffering if they are willing to try ... University case study., After seven weeks of hypnotic relaxation ... following prostate cancer surgery showed a drastic decrease not ... in sleep quality, according to the study., The Baylor ...
Breaking Medicine News(10 mins):Health News:New study shows drinking alcohol provides no heart health benefit 2Health News:Want a higher GPA in college? Join a gym 2Health News:Bacterial colonization prior to catching the flu may protect against severe illness 2Health News:Depressed men with prostate cancer are diagnosed later stage, get less effective therapies 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4
... June 18 Roxane Laboratories, Inc.,announced today ... Application (ANDA),for Ramipril Capsules, 1.25mg, 2.5mg, 5mg ... Administration. The 1.25mg, 2.5mg, 5mg and 10mg ... Roxane Laboratories Ramipril,Capsules are available for immediate ...
... cancer who had abundant vitamin D in their blood were ... who were deficient in the vitamin, according to a new ... of the study -- the first to examine the effect ... research, but it is too early to recommend supplements as ...
... a human patient,s cloned infection-fighting T cells as the sole ... A team led by Cassian Yee, M.D., an associate member ... Center, reports these findings in the June 19 issue of ... and colleagues removed CD4+ T cells, a type of white ...
... Authority continues monitoring and evaluating wrong-site surgeries,with ... wrong-site surgery,update, HARRISBURG, Pa., June 18 ... "National Time Out Day," which is a,national ... time out" before every,operation to confirm correct ...
... DENVER, June 18 Air Methods Corporation,(Nasdaq: ... in the,world, announced today that Chief Executive Officer ... present at the Jefferies 2nd Annual,Healthcare Conference in ... at 11:15,a.m. ET., Interested parties can listen ...
... in Indiana to propose awareness-raising ... legislation in 2009., ... of July as Indiana Safe Haven Month and the,National Safe Haven ... for babies who were adopted thanks to legislation,passed overwhelmingly in the ...
Cached Medicine News:Health News:Roxane Laboratories, Inc. Announces the Launch of Ramipril Capsules 2Health News:Study links vitamin D to colon cancer survival 2Health News:Patient's own infection-fighting T cells put late-stage melanoma into long-term remission 2Health News:Patient Safety Authority Supports 'National Time Out Day' 2Health News:Governor and Lt. Governor Celebrate Eight Years of Safe Haven Babies 2
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... InformEx, North America,s leading business ... hold the 30 th edition of its annual conference ... from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... chemical and specialty chemical companies will take part in the ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... 15 , - Nine-Month Sales (Excluding Technical ... EBITDA Margin at High Level of 17.2% , ... In the first nine months of the financial ... (prior year EUR 783.4m).,Excluding the Technical Plastics business which has been sold, ...
... Minn., Oct. 14 AbbeyMoor Medical Inc. ... CPT code by the American Medical Association (AMA) for ... action, effective in January 2010, upgrades The Spanner from ... Category I procedure code for established procedures. This major ...
Cached Medicine Technology:Gerresheimer has Passed the Turning Point 2Gerresheimer has Passed the Turning Point 3Gerresheimer has Passed the Turning Point 4AbbeyMoor Medical Receives Category I CPT(R) Code for The Spanner(TM) Prostatic Stent Procedure 2AbbeyMoor Medical Receives Category I CPT(R) Code for The Spanner(TM) Prostatic Stent Procedure 3
Clearview RSV is a simple, immunochromatographic assay to aid in the diagnosis of respiratory syncytial virus (RSV) infections in children less than 6 years and adults over age 60....
Clearview ULTRA FOB is a rapid, two-step immunochemical test for the detection of fecal occult blood....
... RTVue is an ultra-high speed, high resolution ... for retina imaging and analysis. ... Fourier-Domain Optical Coherence technology just emerging from ... The ultra-high speed and high ...
The Clearview hCG Test is for the rapid detection of human chorionic gonadotropin (hCG) in urine specimens. This test kit is used to obtain a visual, qualitative result and is intended for professio...
Medicine Products: